Abstract
Direct oral anticoagulants (DOACs) are rapidly changing the way we think about selecting, treating, and monitoring patients in need of anticoagulation. These agents may be used for either treatment or prophylaxis of systemic embolism and have been compared to vitamin K antagonist (e.g., warfarin) for many of the same indications. DOACs bring several advantages over traditional therapies but also reveal a new set of challenges. Pharmacists should be experts in the pharmacology and pharmacokinetics of these medications and have the ability to increase the safe use of DOACs through several avenues. This chapter outlines the role of the pharmacist in the management of DOAC medications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Keisu M, Andersson TB (2010) Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 196:407–418
Diener HC (2006) Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 21:279–293
Tedders KM, Lucey MF, Edwin SB (2013) Evaluation of pharmacist-managed dabigatran in an inpatient setting. Ann Pharmacother 47:1649–1653
Cutler TW, Chuang A, Huynh TD et al (2014) A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Pharm 20:1028–1034
Weitz JI, Gross PL (2012) New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program 2012:536–540
Gonsalves WI, Pruthi RK, Patnaik MM (2013) The new oral anticoagulants in clinical practice. Mayo Clin Proc 88:495–511
Eikelboom JW, Connolly SJ, Brueckmann M et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206–1214
Pradaxa [prescribing information] (2014) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 12/2014
Pradaxa [product monograph] (2014) Boehringer Ingelheim Canada Ltd., Burlington, 12/2014
Pradaxa [summary of product characteristics] (2014) Boehringer Ingelheim Pharma, Ingelheim, 12/2014
Xarelto [prescribing information] (2014) Janssen Pharmaceuticals, Inc., Titusville, 12/2014
Xarelto [product monograph] (2014) Bayer Inc., Toronto, 12/2014
Xarelto [summary of product characteristics] (2013) Bayer Pharma, Leverkusen, 5/2013
Eliquis [prescribing information] (2014) Bristol-Myers Squibb Company, Princeton, 8/2014
Eliquis [product monograph] (2014) Pfizer Canada Inc., Kirkland, 12/2014
Eliquis [summary of product characteristics] (2014) Bristol-Myers Squibb, Anagni (FR) 12/2014
Savaysa [prescribing information] (2015) Daiichi Sankyo, Inc, Parsippany, 1/2015
Hong C, Kim S, Curnew G et al (2013) Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol 20:e229–e237
Ageno W, Crowther M, Baglin T et al (2013) Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11:177–179
Miyares MA, Davis K (2012) Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 69:1473–1484
Morishima Y, Kamisato C (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban. Am J Clin Pathol 143:241–247
Hellwig T, Gulseth M (2013) Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother 47:1478–1487
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708
Abo-Salem E, Becker R (2014) Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. J Thromb Thrombolysis 37:372–379
Siegal DM (2015) Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39:395–402
Patel J, White R, Finley K (2015) Effect of target-specific oral anticoagulants on a pharmacist-managed anticoagulation clinic. Am J Health Syst Pharm 72:16–17
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Robinson, E. (2015). Direct Oral Anticoagulants. In: Rose, A. (eds) Anticoagulation Management. Adis, Cham. https://doi.org/10.1007/978-3-319-22602-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-22602-6_4
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-22601-9
Online ISBN: 978-3-319-22602-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)